Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.
Adamichou C, Flouri I, Fanouriakis A, Nikoloudaki M, Nikolopoulos D, Repa A, Boki K, Chatzidionysiou K, Garyfallos A, Boumpas D, Sidiropoulos P, Bertsias G. Adamichou C, et al. Among authors: nikoloudaki m. Mediterr J Rheumatol. 2020 Mar 31;31(1):87-91. doi: 10.31138/mjr.31.1.87. eCollection 2020 Mar. Mediterr J Rheumatol. 2020. PMID: 32411939 Free PMC article.
Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus.
Adamichou C, Genitsaridi I, Nikolopoulos D, Nikoloudaki M, Repa A, Bortoluzzi A, Fanouriakis A, Sidiropoulos P, Boumpas DT, Bertsias GK. Adamichou C, et al. Among authors: nikoloudaki m. Ann Rheum Dis. 2021 Jun;80(6):758-766. doi: 10.1136/annrheumdis-2020-219069. Epub 2021 Feb 10. Ann Rheum Dis. 2021. PMID: 33568388 Free PMC article.
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events.
Nikolopoulos D, Loukogiannaki C, Sentis G, Garantziotis P, Manolakou T, Kapsala N, Nikoloudaki M, Pieta A, Flouda S, Parodis I, Bertsias G, Fanouriakis A, Filia A, Boumpas DT. Nikolopoulos D, et al. Among authors: nikoloudaki m. Ann Rheum Dis. 2024 Apr 12:ard-2024-225664. doi: 10.1136/ard-2024-225664. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38609158 Free article.
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment.
Dedemadi AG, Gkolfinopoulou C, Nikoleri D, Nikoloudaki M, Ruhanen H, Holopainen M, Kakela R, Christopoulou G, Bournazos S, Constantoulakis P, Sidiropoulos P, Bertsias G, Chroni A. Dedemadi AG, et al. Among authors: nikoloudaki m. Rheumatology (Oxford). 2024 Mar 21:keae192. doi: 10.1093/rheumatology/keae192. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38514392
Comorbidities Burden and Implementation of the Treat-to-Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides.
Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Pateromichelaki K, Marolachaki E, Terizaki M, Nikoloudaki M, Eskitzis A, Kalogiannaki E, Bertsias G, Sidiropoulos P. Flouri ID, et al. Among authors: nikoloudaki m. Mediterr J Rheumatol. 2023 Jul 31;34(4):581-587. doi: 10.31138/mjr.310723.cba. eCollection 2023 Dec. Mediterr J Rheumatol. 2023. PMID: 38282943 Free PMC article.
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G. Pitsigavdaki S, et al. Among authors: nikoloudaki m. Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919. Ann Rheum Dis. 2024. PMID: 38233103 Free PMC article.
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, Katsimbri P, Theotikos E, Pitsigavdaki S, Pateromichelaki K, Bertsias A, Elezoglou A, Sidiropoulos P, Fanouriakis A, Boumpas D, Bertsias G. Nikoloudaki M, et al. Front Immunol. 2023 Jan 4;13:1074044. doi: 10.3389/fimmu.2022.1074044. eCollection 2022. Front Immunol. 2023. PMID: 36685524 Free PMC article.
11 results